TapewireFind a company

person · Reporting owner

Poukalov Konstantin

Disclosed activity across 8 companies

Tapewire entity
88627
SEC CIK
0001678736

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ARYA Sciences Acquisition Corp VARYE · Entity 137308Chief Business OfficerJuly 12, 2021July 12, 2021
Cerevel Therapeutics Holdings, Inc.ARYB · Entity 15182Chief Business OfficerJune 04, 2020June 04, 2020
Kadmon Holdings, Inc.KDMN · Entity 133686Executive Vice President, CFODecember 08, 2017December 12, 2017
Landos Biopharma, Inc.LABP · Entity 90644Director · 10% ownerFebruary 05, 2021February 09, 2021
LianBioLIAN · Entity 9881DirectorFebruary 15, 2024February 20, 2024
Lyra Therapeutics, Inc.LYRA · Entity 46837DirectorJune 13, 2024June 14, 2024
Nautilus Biotechnology, Inc.ARYA · Entity 6679Chief Business OfficerAugust 06, 2020August 07, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARYA Sciences Acquisition Corp V

Report date July 12, 2021 · Filed July 12, 2021

This filing explicitly reported no securities owned.

Cerevel Therapeutics Holdings, Inc.

Report date June 04, 2020 · Filed June 04, 2020

This filing explicitly reported no securities owned.

Kadmon Holdings, Inc.

Report date December 08, 2017 · Filed December 12, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2027-12-08Direct205,000 Reported balance After 2017-12-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2017-12-08 · Grant · Acquired 205,000 · Balance 205,000

F1: The stock appreciation right vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The stock appreciation right vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant.

Landos Biopharma, Inc.

Report date February 05, 2021 · Filed February 09, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy funds14,869,915 Last balance in matching sequence After 2021-02-09 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rows

Row 1 · 2021-02-05 · Purchase · Acquired 27,453 · Balance 14,647,181

F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F2: These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.

F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Row 2 · 2021-02-08 · Purchase · Acquired 34,611 · Balance 14,681,792

F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F4: These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.

F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Row 3 · 2021-02-08 · Purchase · Acquired 86,671 · Balance 14,768,463

F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F5: These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.

F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Row 4 · 2021-02-08 · Purchase · Acquired 1,771 · Balance 14,770,234

F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F6: These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.

F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Row 5 · 2021-02-09 · Purchase · Acquired 64,730 · Balance 14,834,964

F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F7: These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.

F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Row 6 · 2021-02-09 · Purchase · Acquired 34,951 · Balance 14,869,915

F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F8: These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.

F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F2: These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.

F3: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4: These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.

F5: These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.

F6: These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.

F7: These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.

F8: These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.

LianBio

Report date February 15, 2024 · Filed February 20, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect17,082 Ending reported balance After 2024-02-15 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2024-02-15 · Exercise / conversion · Acquired 36,300 · Balance 36,300

Row 2 · 2024-02-15 · Tax withholding · Disposed 19,218 · Balance 17,082

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2032-06-23Direct0 Reported balance After 2024-02-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-02-15 · Exercise / conversion · Disposed 36,300 · Balance 0

Lyra Therapeutics, Inc.

Report date June 13, 2024 · Filed June 14, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2034-06-12Direct30,000 Reported balance After 2024-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-13 · Grant · Acquired 30,000 · Balance 30,000

F1: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

Nautilus Biotechnology, Inc.

Report date August 06, 2020 · Filed August 07, 2020

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARYA Sciences Acquisition Corp IV

Report date July 31, 2024 · Filed July 31, 2024

Section 16 reporting ended · disclosed 2024-07-31. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 13, 2024 Filed Jun 14, 2024 20:10 UTC Lyra Therapeutics, Inc. LYRA · Entity 46837 GrantStock Option · Derivative 30,000 $0.00 Strike: $0.31 $0.00
Disclosure

SEC source: 0000950170-24-073650 · ownership.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 22:27 UTC LianBio LIAN · Entity 9881 Exercise / conversionStock Option (Right to Buy) · Derivative 36,300 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001062993-24-003733 · form4.xml · derivative · entry 3

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 36,300 shares

Expires 2032-06-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 15, 2024 Filed Feb 20, 2024 22:27 UTC LianBio LIAN · Entity 9881 Tax withholdingOrdinary Shares 19,218 $4.76 $91,477.68
Disclosure

SEC source: 0001062993-24-003733 · form4.xml · nonDerivative · entry 2

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,082

Read SEC document
February 15, 2024 Filed Feb 20, 2024 22:27 UTC LianBio LIAN · Entity 9881 Exercise / conversionOrdinary Shares 36,300 $2.52 $91,476.00
Disclosure

SEC source: 0001062993-24-003733 · form4.xml · nonDerivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 30, 2023 Filed Jul 6, 2023 01:50 UTC Lyra Therapeutics, Inc. LYRA · Entity 46837 GrantStock Option · Derivative 20,000 $0.00 Strike: $4.11 $0.00
Disclosure

SEC source: 0000950170-23-031869 · ownership.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2033-06-29

F1 · derivative.exercise_date: This option vests and becomes exercisable on June 30, 2024, subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:10 UTC LianBio LIAN · Entity 9881 GrantStock Option (Right to Buy) · Derivative 36,300 $0.00 Strike: $2.40 $0.00
Disclosure

SEC source: 0001062993-23-013980 · form4.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,300

Underlying: Ordinary Shares · 36,300 shares

Expires 2033-06-21

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

Read SEC document
June 23, 2022 Filed Jun 27, 2022 21:37 UTC LianBio LIAN · Entity 9881 GrantStock Option (Right to Buy) · Derivative 36,300 $0.00 Strike: $2.52 $0.00
Disclosure

SEC source: 0001062993-22-015490 · form4.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,300

Underlying: Ordinary Shares · 36,300 shares

Expires 2032-06-23

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

Read SEC document
June 16, 2022 Filed Jun 21, 2022 20:06 UTC Lyra Therapeutics, Inc. LYRA · Entity 46837 GrantStock Option · Derivative 7,250 $0.00 Strike: $5.09 $0.00
Disclosure

SEC source: 0000899243-22-023337 · doc4.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,250

Underlying: Common Stock · 7,250 shares

Expires 2032-06-15

F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 16, 2023 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

Read SEC document
May 26, 2021 Filed May 28, 2021 22:25 UTC Lyra Therapeutics, Inc. LYRA · Entity 46837 GrantStock Option · Derivative 7,250 $0.00 Strike: $7.24 $0.00
Disclosure

SEC source: 0000899243-21-021189 · doc4.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,250

Underlying: Common Stock · 7,250 shares

Expires 2031-05-25

F1 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) May 26, 2022 (the one-year anniversary of the date of grant) and (ii) the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Non-Employee Director's continued service on the Board as a Non-Employee Director through such vesting date.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 19:56 UTC Landos Biopharma, Inc. LABP · Entity 90644 PurchaseCommon Stock 34,951 $14.60 $510,284.60
Disclosure

SEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 6

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 14,869,915

F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F8 · price: These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.

F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
February 09, 2021 Filed Feb 9, 2021 19:56 UTC Landos Biopharma, Inc. LABP · Entity 90644 PurchaseCommon Stock 64,730 $13.80 $893,274.00
Disclosure

SEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 5

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 14,834,964

F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F7 · price: These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.

F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2021 Filed Feb 8, 2021 18:08 UTC Landos Biopharma, Inc. LABP · Entity 90644 ConversionSeries B Preferred Stock · Derivative 7,486,190 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008587 · doc4.xml · derivative · entry 4

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 0

Underlying: Common Stock · 7,486,190 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.

F7 · shares: Consists of 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PLSMF, 2,857,795 shares of common stock issuable upon conversion of Series B preferred stock held by PXVF and 1,770,600 shares of common stock issuable upon conversion of Series B preferred stock held by PXV. Perceptive Advisors serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.

F2 · derivative.exercise_date: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.

F2 · derivative.expiration_date: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.

F4 · ownership.nature: Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2021 Filed Feb 8, 2021 18:08 UTC Landos Biopharma, Inc. LABP · Entity 90644 ConversionSeries A Preferred Stock · Derivative 5,883,538 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008587 · doc4.xml · derivative · entry 3

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 0

Underlying: Common Stock · 5,883,538 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.

F6 · shares: Consists of 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PLSMF and 2,941,769 shares of common stock issuable upon conversion of Series A preferred stock held by PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.

F1 · derivative.exercise_date: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.

F1 · derivative.expiration_date: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.

F5 · ownership.nature: Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2021 Filed Feb 8, 2021 18:08 UTC Landos Biopharma, Inc. LABP · Entity 90644 PurchaseCommon Stock 1,250,000 $16.00 $20,000,000.00
Disclosure

SEC source: 0001209191-21-008587 · doc4.xml · nonDerivative · entry 2

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 14,619,728

F4 · ownership.nature: Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F5 · ownership.nature: Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2021 Filed Feb 8, 2021 18:08 UTC Landos Biopharma, Inc. LABP · Entity 90644 ConversionCommon Stock 13,369,728 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-008587 · doc4.xml · nonDerivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 13,369,728

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's Series A preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.

F2 · price: Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.

F3 · balance_after: Consists of 5,799,564 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), 5,799,564 shares of common stock held by Perceptive Xontogeny Venture Fund, LP ("PXVF"), and 1,770,600 shares of common stock held by PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4 · ownership.nature: Securities are held by PLSMF, PXVF, and PXV. Perceptive Advisors serves as the investment manager to Perceptive PLSMF, PXVF, and PXV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

F5 · ownership.nature: Securities are held by PLSMF and PXVF. Perceptive Advisors serves as the investment manager to PLSMF and PXVF. and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a Managing Director of Perceptive Advisors and may be deemed to indirectly beneficially own the securities. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2021 Filed Feb 9, 2021 19:56 UTC Landos Biopharma, Inc. LABP · Entity 90644 PurchaseCommon Stock 1,771 $13.10 $23,200.10
Disclosure

SEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 4

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 14,770,234

F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F6 · price: These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.

F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2021 Filed Feb 9, 2021 19:56 UTC Landos Biopharma, Inc. LABP · Entity 90644 PurchaseCommon Stock 86,671 $12.53 $1,085,987.63
Disclosure

SEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 3

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 14,768,463

F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F5 · price: These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.

F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
February 08, 2021 Filed Feb 9, 2021 19:56 UTC Landos Biopharma, Inc. LABP · Entity 90644 PurchaseCommon Stock 34,611 $11.38 $393,873.18
Disclosure

SEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 2

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 14,681,792

F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F4 · price: These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.

F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
February 05, 2021 Filed Feb 9, 2021 19:56 UTC Landos Biopharma, Inc. LABP · Entity 90644 PurchaseCommon Stock 27,453 $11.14 $305,826.42
Disclosure

SEC source: 0001209191-21-009047 · doc4.xml · nonDerivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By funds

Disclosed balance after: 14,647,181

F1 · price: The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.

F2 · price: These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.

F3 · ownership.nature: Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Read SEC document
April 30, 2020 Filed May 1, 2020 22:38 UTC Lyra Therapeutics, Inc. LYRA · Entity 46837 GrantStock Option · Derivative 14,500 $0.00 Strike: $16.00 $0.00
Disclosure

SEC source: 0000899243-20-011751 · doc4.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,500

Underlying: Common Stock · 14,500 shares

Expires 2030-04-29

F1 · derivative.exercise_date: This option vests and becomes exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020.

Read SEC document
December 08, 2017 Filed Dec 12, 2017 16:08 UTC Kadmon Holdings, Inc. KDMN · Entity 133686 GrantStock Appreciation Right · Derivative 205,000 $0.00 Strike: $3.64 $0.00
Disclosure

SEC source: 0001593968-17-001351 · primary_01.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,000

Underlying: Common Stock, par value $0.001 · 205,000 shares

Expires 2027-12-08

F1 · derivative.exercise_date: The stock appreciation right vests and becomes exercisable in three equal annual installments over 3 years from December 8, 2017, the date of grant.

Read SEC document
December 15, 2016 Filed Dec 16, 2016 20:22 UTC Kadmon Holdings, Inc. KDMN · Entity 133686 GrantStock Option (right to buy) · Derivative 350,000 $4.66 Strike: $4.66 $1,631,000.00
Disclosure

SEC source: 0001593968-16-001349 · primary_01.xml · derivative · entry 1

Poukalov Konstantin · CIK 0001678736 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock, par value $0.001 · 350,000 shares

Expires 2026-12-15

F1 · derivative.exercise_date: The option becomes vested and exercisable in three equal annual installments over 3 years from December 15, 2016, the date of grant, with vesting to accelerate if employment ends for any reason other than a termination for Cause, as defined in the relevant employment agreement.

F2 · balance_after: Only represents derivative securities of this class.

Read SEC document
November 11, 2016 Filed Nov 14, 2016 08:41 UTC Kadmon Holdings, Inc. kdmn · Entity 133686 PurchaseCommon stock, par value $0.001 1,000 $5.43 $5,430.00
Disclosure

SEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 4

Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Read SEC document
November 11, 2016 Filed Nov 14, 2016 08:41 UTC Kadmon Holdings, Inc. kdmn · Entity 133686 PurchaseCommon stock, par value $0.001 1,000 $5.95 $5,950.00
Disclosure

SEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 3

Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Read SEC document
November 11, 2016 Filed Nov 14, 2016 08:41 UTC Kadmon Holdings, Inc. kdmn · Entity 133686 PurchaseCommon stock, par value $0.001 1,000 $5.91 $5,910.00
Disclosure

SEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 2

Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Read SEC document
November 11, 2016 Filed Nov 14, 2016 08:41 UTC Kadmon Holdings, Inc. kdmn · Entity 133686 PurchaseCommon stock, par value $0.001 1,000 $5.96 $5,960.00
Disclosure

SEC source: 0001557142-16-000040 · primary_doc.xml · nonDerivative · entry 1

Poukalov Konstantin · CIK 0001678736 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.